Global Burden of Disease

Mental Disorders and Illicit Drug Use Expert Group

Summary of data collected and decision rules used in making regional and global estimates:

Conduct Disorder

Adele Somerville, Amanda Baxter, Paul Nelson, An Pham, Allison Ventura, Roman Scheurer, Bianca Calabria, Jen McLaren, Anna Roberts, Louisa Degenhardt and Harvey Whiteford *for the Mental Disorders and Illicit Drug Use Expert Group*

Summary of data collected and decision rules used in making regional and global estimates:

Conduct Disorder

Adele Somerville, Amanda Baxter, Paul Nelson, An Pham, Allison Ventura, Roman Scheurer, Bianca Calabria, Jen McLaren, Anna Roberts, Louisa Degenhardt and Harvey Whiteford *for the Mental Disorders and Illicit Drug Use Expert Group*

Working Paper

Acknowledgments:

The Mental Disorders and Illicit Drug Use Expert Group comprise: Prof Harvey Whiteford (Co-Chair), Prof Louisa Degenhardt (Co-Chair), Prof Oye Gureje, Prof Wayne Hall, Dr Cille Kennedy, Prof Ron Kessler, Prof John McGrath, Dr Maria Medina-Mora, Dr Guilherme Polanczyk, Prof Martin Prince, and Dr Shekhar Saxena.

The authors wish to express their gratitude to staff of The Park, Centre for Mental Health Library and the University of Queensland Library, Ms Amanda Brown, Mrs Keryl Michener, Paul Nelson and all colleagues who assisted in the data search and extraction.

Table of Contents

Glossary

ARR	Annualised remission rate
CD	Conduct Disorder
CIDI	Composite International Diagnostic Interview
DALY	Disability-adjusted life year
DSM	Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association)
GBD	Global Burden of Disease Project
ICD	International Classification of Diseases (World Health Organisation)
LP	Lifetime prevalence
ODD	Oppositional Defiant Disorder
PMP	Past month prevalence
PYP	Past year prevalence
WHO	World Health Organisation
WMHS	World Mental Health Survey
YLD	Years of life lived with disability
YLL	Years of life lost

Preliminary data coverage identified for: Conduct disorder

Figure 1. Past month, past year and lifetime prevalence estimate coverage for conduct disorder, including WMHS data.



1.0 Data summary and decision rules overview

The new Global Burden of Disease study commenced in 2007 and is the first major effort since the original 1996 GBD study to produce systematic and comprehensive estimates of the burden of diseases and injuries. It will also update the comparative estimates of the burden of risk factors. While the original 1996 GBD study produced 1990 estimates for 107 diseases and injuries and ten risk factors for eight world regions, the new study will produce 1990 and 2005 estimates for 150 diseases and injuries and more than 40 risk factors for 21 regions of the world.

Important changes will be made to the scope and nature of the estimates for mental disorders and illicit drug use. More disorders are being considered because of significant advances in epidemiological research. The original study contained estimates for unipolar depression, bipolar disorder, panic disorder, obsessive compulsive disorder, post traumatic stress disorder and illicit drug use. The new estimates will include the mental disorders covered in the original study plus eating disorders (both anorexia and bulimia), dysthymia (as well as major depression), generalised anxiety disorder, agoraphobia, social phobia, specific phobia, separation anxiety disorder, pervasive developmental disorders (autism and Asperger's disorder), attention deficit hyperactivity disorder and conduct disorder.

This document focuses on the conduct disorder preliminary dataset.

1.1 Data sources

A systematic review was undertaken to identify sources of data containing epidemiologic parameters for conduct disorders. Papers identified in the search were sought and data containing these parameters were extracted, recorded and standardised.

Standardised approaches to literature searches, data collection, data extraction, consistency and error checking, and expert consultation and review were taken across mental disorders. These methodologies are documented and detailed on the expert group's website: www.gbd.unsw.edu.au., but briefly can be summarised as follows:

Stages of the Systematic Review

1. Search of peer-reviewed literature. The search strategy is consistent with the methodology recommended by the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group[1]. Three electronic databases were included in the search (Medline, PsychInfo and Embase), with searches limited to human subjects and publication dates of 1980 to 2007. Search strings are available for review at: http://www.gbd.unsw.edu.au/gbdweb.nsf/page/Methodology.

2. Identifying articles from peer-reviewed literature that met inclusion criteria. An extensive list of articles was picked up by the search string. From this list of several thousand articles, each was briefly reviewed for the following inclusion criteria:

- Must include the specific disorder under review;
- Must present primary data;
- Must be an epidemiologic study (pharmacological treatment samples and case studies excluded);
- Must present data for the period 1980 onward;
- When general population data at a national level were available sub-national data were excluded;
- Samples must be representative of the general population.

3. Obtaining full-text copies of articles. The references of articles identified from the systematic review were compiled in Endnote.

4. Data extraction. A three-level Access database was designed to accommodate the data from the mental disorders systematic search. A random sample of articles was double-checked for accuracy and consistency of data extraction and entry. In-built quality assurance was a feature of the Access database through the use of drop-down boxes and coding protocols.

A Quality Index Score was developed based on a range of variables extracted from each identified source of data so that the representativeness of studies can be quantified and used for comparison. The Quality Index Score is available for review at :

http://www.gbd.unsw.edu.au/gbdweb.nsf/resources/MD_Pt2_Appendicies/$file/GBD2005+Mental+Disorders+Quality+Index.pdf.

In this document we present an initial summary of the prevalence data identified for conduct disorder.

We present the decision rules relating to :

- inclusion criteria for data sources,
- methodology of data extraction, and
- reporting of study characteristics and epidemiologic parameters.

Also presented here are some preliminary decision rules for:

- manipulating data,
- imputing missing data,
- pooling data within countries,
- pooling data for some parameters (for example remission and mortality), and
- our approach to production of regional prevalence estimates for mental disorders as a whole.

Further work is currently underway to identify peer-reviewed and grey literature sources that may assist with missing age-, sex- and country-specific estimates. The process of applying the rules outlined below has begun, with the first steps presented in this document.

2.0 Principles for inclusion of data sources and reporting of data.

Presented here are general rules for the inclusion of articles and data identified through the peer-review literature and through expert review. We also present the general protocol and rules for reporting of data.

2.1 Inclusion of Data Sources (including Peer-review papers)

Peer-review literature versus grey literature

A preliminary search for epidemiologic data for mental disorders identified a range of sources, including grey literature (government reports, unpublished findings, dissertations), peer-review publications and non-government organisation (NGO) data collection. Due to the wealth of data available (including data from the World Mental Health Survey) and the available time frame, the decision was taken to focus the first stage of the data search on peer-reviewed literature. Grey literature sources will be reviewed in the second stage of the project as data sources to address the gaps in the preliminary dataset.

Justification: A large body of data is available through the peer-review literature, of sufficient quality to meet the expert group's criteria, to provide a preliminary dataset for the first round of estimates. It is anticipated that the circulation of these preliminary findings to experts in the field will yield a range of very useful suggestions for other data sources, including grey literature, to address the gaps in the data. In this way it is anticipated that maximum coverage will be achieved.

Representativeness

Where a large body of data is available for a country (e.g. for the US, Western Europe, Great Britain, New Zealand and Australia), only the nationally representative studies will be included.

Justification: Excluding studies that have small samples that are likely NOT representative of the national population will be a more time-efficient process. Studies with unrepresentative samples are unlikely to be used for this GBD Project.

Diagnostic Criteria

A broad rule was adopted for all mental disorders that initial data collection for prevalence, incidence and remission would be limited to data sources reporting estimates based on DSM or ICD diagnostic criteria only. Papers that report use of a survey that could not demonstrate validity against either DSM or ICD criteria were excluded. If the validity of a survey is uncertain, the opinion of an expert in the field will be sought.

Justification: Inclusion of estimates based on alternative definitions may skew the final estimates for some countries, as narrower or broader definitions would result in lower or higher estimates.

Definition of Remission

For the Global Burden of Disease project, remission from a mental disorder is defined as no longer fulfilling the diagnostic criteria for this disorder. Partial remission is therefore considered as being no longer a "case". Follow-up period for the sample must be a minimum of two years.

Remission estimates were obtained from observational studies. Studies that reported samples from randomised controlled trials or treatment other than "as usual" will be excluded as not being representative of the average case. Remission among cases of mental disorders *in treatment* (that is, treatment "as usual") will not be considered separately from out-of-treatment cases as so little data are available from community (non-treated) samples.

If several papers have been published for the same study (i.e. same cohort) at different time points, only the paper reporting the longest follow-up period will be included in the dataset.

2.2 Data Extraction and Reporting

Prevalence rate

If prevalence type was unspecified, the diagnostic tool was sought in order to determine whether prevalence was point, past month, 12-month, lifetime or another period. If the diagnostic tool was unable to be accessed or unclear, prevalence was taken as point. An exception to this rule was for samples ascertained through case registries. As these were diagnosed with the disorder AT SOME PERIOD in their lives, but possibly some time ago, prevalence was taken as lifetime. As this was most frequently the case for disorders with zero remission in studies that used birth cohorts (e.g. autism), it is assumed that this will not make a significant difference to the rate.

Cohort

Cohort size was defined in different ways according to the methods used in the studies. Typically, cohort size was defined as the sample size, specifically the number of individuals for whom useable data was collected.

However, if the sample was derived from a case register or from medical records for a geographically defined area, and:

- the degree of coverage is difficult to ascertain due to inadequate reporting, or
- coverage appears to be poor (e.g. those who seek treatment in countries where a state-funded health system is not cheaply and easily accessible), or
- coverage is reliant on an individual actively seeking treatment for a disorder that is known to have a low level of treated prevalence (e.g. depression),

then the cohort size was recorded as the number of cases identified.

Alternatively, where health checks are legislated for infants and children at regular intervals (e.g. Norway and Japan) and coverage is close to 100% (95% or higher), cohort is taken as the number of children in that age group who fall within the defined area, as we can reasonably expect that data has been obtained for that number of people.

Time period (Epoch)

- Epoch not reported

Where epoch (the year to which the estimate refers) is NOT reported within a paper, a note will be made of the fact and epoch recorded as the year two years prior to publication.

Justification: The GBD Project requires the year of the estimate in order to establish a time trend for calculation of burden. However the research team found that it is relatively common for authors to not report details such as epoch, response rate, etc. Rather than leave a gap in the data where epoch is not reported, an overall decision was taken to estimate the epoch as two years prior to publication, on the basis that it will generally take at least two years to clean data, carry out analysis and publish results.

- Longitudinal studies

Where data collection is carried out over a period of time, the midpoint of the data collection period was taken as epoch start and midpoint of final follow-up period as epoch end. For example, if baseline data collection is 1980–1982 and final follow-up period is 2000–2004, epoch start is recorded as 1981 and epoch end as 2002. Greater detail of different time periods is recorded as text in the comments field.

- Studies that give estimates for different time periods

Where a longitudinal study gives year-specific estimates, the years that those estimates relate to are recorded as epoch start and epoch end. Again, greater detail is recorded as text in the comments field of the database. For example, if a longitudinal study reports 12-month prevalence for two samples, one ascertained 1980–1981 and the other 1990–1991, epoch is recorded as 1980–1981 for the prevalence rate specific to that particular time period and 1990–1991 for the relevant prevalence estimate.

Age Range

Where an age range is not reported in the paper, 'dummy' variables of 0 (minimum) and 99 (maximum) are inserted. If the sample is reported as 'adult' the age range was recorded as 18–99.

Remission and Mortality – Secondary Data Sources

In all cases, the primary source of data was used for all surveys for data extraction purposes. However, due to time restrictions, when a study reported data from previous years this data was included with a note that it did not come from the primary data source. Similarly, where a good quality systematic review or meta-analysis was identified, the data reported was included and clearly identified as coming from a secondary data source.

3.0 Data sources for conduct disorder

3.1 Prevalence data

Table 1 presents the available data identified from an extensive search of the peer review literature (see www.gbd.unsw.edu.au for methodology). Citations for data sources are given in columns 2 to 4. All data sources can be obtained from the reference list at the end of this report. The last two columns indicate whether ANY sex- and age- specific estimates were reported for that country (Y=Yes, N=No).

Table 1. Summary of data available by country for prevalence of conduct disorder (CD and ODD), including the WMHS data.

Region /Country	CD – Past month prevalence (PMP)	CD – Past year prevalence (PYP)	CD – Lifetime prevalence (LP)	Age-specific Estimates	Sex-specific Estimates
Asia Pacific, High Income					
Brunei	–	–	–	–	–
Japan	–	–	–	–	_
Republic of Korea (South Korea)	–	–	–	–	_
Singapore	–	–	–	–	_
Asia, Central					
Armenia	–	–	–	–	–
Azerbaijan	–	–	–	–	–
Georgia	–	–	–	–	–
Kazakhstan	–	–	–	–	–
Kyrgyzstan	–	–	–	–	–
Mongolia	–	–	–	–	–
Tajikistan	–	–	–	–	–
Turkmenistan	–	–	–	–	–
Uzbekistan	–	–	–	–	–
Asia, East					
China	–	[2]	[2]	Y	Y
Hong Kong	[3]	–	–	N	Y
Democratic People's Republic of Korea (North Korea)	–	–	–	–	–
Taiwan	–	[4]	–	Y	N

Region /Country	CD – Past month prevalence (PMP)	CD – Past year prevalence (PYP)	CD – Lifetime prevalence (LP)	Age-specific Estimates	Sex-specific Estimates
Asia, South					
Afghanistan	–	–	–	–	–
Bangladesh	–	[5]	–	N	N
Bhutan	–	–	–	–	–
India	[6], [7]	–	–	N	N
Nepal	–	–	–	–	–
Pakistan	–	–	–	–	–
Asia, Southeast					
Cambodia	–	–	–	–	–
Indonesia	–	–	–	–	–
Lao People's Democratic Republic	–	–	–	–	–
Malaysia	–	[8]	–	N	Y
Maldives	–	–	–	–	–
Mauritius	–	–	–	–	–
Mayotte	–	–	–	–	–
Myanmar	–	–	–	–	–
Philippines	–	–	–	–	–
Reunion Island	–	–	–	–	–
Seychelles	–	–	–	–	–
Sri Lanka	–	–	–	–	–
Thailand	–	–	–	–	–
Timore Leste	–	–	–	–	–
Viet Nam	–	–	–	–	–
Australasia					
Australia	–	[9]	–	N	Y
New Zealand	[10], [11]	[12], [13], [14]	–	N	Y
Caribbean					
Anguilla	–	–	–	–	–
Antigua and Barbuda	–	–	–	–	–
Aruba	–	–	–	–	–
Bahamas	–	–	–	–	–
Barbados	–	–	–	–	–
Belize	–	–	–	–	–
Bermuda	–	–	–	–	–
British Virgin Islands	–	–	–	–	–
Cayman Islands	–	–	–	–	–

Region /Country	CD – Past month prevalence (PMP)	CD – Past year prevalence (PYP)	CD – Lifetime prevalence (LP)	Age-specific Estimates	Sex-specific Estimates
Cuba	–	–	–	–	–
Dominica	–	–	–	–	–
Dominican Republic	–	–	–	–	–
French Guiana	–	–	–	–	–
Grenada	–	–	–	–	–
Guadaloupe	–	–	–	–	–
Guyana	–	–	–	–	–
Haiti	–	–	–	–	–
Jamaica	–	–	–	–	–
Martinique	–	–	–	–	–
Montserrat	–	–	–	–	–
Netherlands Antilles	–	–	–	–	–
Puerto Rico	[15]	[16]	–	N	Y
Saint Kitts and Nevis	–	–	–	–	–
St. Lucia	–	–	–	–	–
St. Vincent	–	–	–	–	–
Suriname	–	–	–	–	–
Trinidad and Tobago	–	–	–	–	–
Turks and Caicos Islands	–	–	–	–	–
Europe, Central					
Albania	–	–	–	–	–
Bosnia and Herzegovina	–	–	–	–	–
Bulgaria	–	[2]	[2]	Y	Y
Croatia	–	–	–	–	–
Czech Republic	–	–	–	–	–
Hungary	–	–	–	–	–
Kosovo	–	–	–	–	–
Poland	–	–	–	–	–
Romania	–	[2]	[2]	Y	Y
Serbia and Montenegro	–	–	–	–	–
Slovakia	–	–	–	–	–
Slovenia	–	–	–	–	–
The Former Yugoslav Republic of Macedonia	–	–	–	–	–
Yugoslavia	–	–	–	–	–
Europe, Eastern					
Belarus	–	–	–	–	–
Estonia	–	–	–	–	–

Region /Country	CD – Past month prevalence (PMP)	CD – Past year prevalence (PYP)	CD – Lifetime prevalence (LP)	Age-specific Estimates	Sex-specific Estimates
Latvia	–	–	–	–	–
Lithuania	–	–	–	–	–
Republic of Moldova	–	–	–	–	–
Russian Federation	–	–	–	–	–
Ukraine	–	[2]	[2]	Y	Y
Europe, Western					
Andorra	–	–	–	–	–
Austria	–	–	–	–	–
Belgium	–	[2]	[2]	Y	Y
Channel Islands	–	–	–	–	–
Cyprus	–	–	–	–	–
Denmark	–	–	–	–	–
Faeroe Islands	–	–	–	–	–
Finland	–	[17]	–	N	Y
France	–	[2], [18]	[2]	Y	Y
Germany	–	[2], [19]	[2]	Y	Y
Gibraltar	–	–	–	–	–
Greece	–	–	–	–	–
Greenland	–	–	–	–	–
Holy See	–	–	–	–	–
Iceland	–	–	–	–	–
Ireland	–	–	–	–	–
Isle of Man	–	–	–	–	–
Israel	–	–	–	–	–
Italy	–	[2]	[2]	Y	Y
Liechtenstein	–	–	–	–	–
Luxembourg	–	–	–	–	–
Malta	–	–	–	–	–
Monaco	–	–	–	–	–
Netherlands	–	[2], [20]	[2]	Y	Y
Norway	[21]	–	–	N	N
Portugal	–	–	–	–	–
Saint Pierre et Miquelon	–	–	–	–	–
San Marino	–	–	–	–	–
Spain	–	[2]	[2]	Y	Y
Sweden	–	–	–	–	–
Switzerland	–	–	–	–	–

Region /Country	CD – Past month prevalence (PMP)	CD – Past year prevalence (PYP)	CD – Lifetime prevalence (LP)	Age-specific Estimates	Sex-specific Estimates
United Kingdom	[22], [23], [24]	[25]	–	Y	Y
Latin America, Andean					
Bolivia	–	–	–	–	–
Ecuador	–	–	–	–	–
Peru	–	–	–	–	–
Latin America, Central					
Colombia	[26]	[2]	[2]	Y	Y
Costa Rica	–	–	–	–	–
El Salvador	–	–	–	–	–
Guatemala	–	–	–	–	–
Honduras	–	–	–	–	–
Mexico	–	[2]	[2], [27]	Y	Y
Nicaragua	–	–	–	–	–
Panama	–	–	–	–	–
Venezuela	–	–	–	–	–
Latin America, Southern					
Argentina	–	–	–	–	–
Chile	–	–	–	–	–
Falkland Islands (Malvinas)	–	–	–	–	–
Uruguay	–	–	–	–	–
Latin America, Tropical					
Brazil	[28]	[2]	[2]	Y	Y
Paraguay	–	–	–	–	–
North Africa/Middle East					
Algeria	–	–	–	–	–
Bahrain	–	–	–	–	–
Egypt	–	–	–	–	–
Iran (Islamic Republic of)	–	–	–	–	–
Iraq	[29]	–	–	Y	Y
Jordan	–	–	–	–	–
Kuwait	–	–	–	–	–
Lebanon	–	[2]	[2]	Y	Y
Libyan Arab Jamahiriya	–	–	–	–	–
Morocco	–	–	–	–	–
Occupied Palestinian Territory	–	–	–	–	–
Oman	–	–	–	–	–
Qatar	–	–	–	–	–

Region /Country	CD – Past month prevalence (PMP)	CD – Past year prevalence (PYP)	CD – Lifetime prevalence (LP)	Age-specific Estimates	Sex-specific Estimates
Saudi Arabia	–	–	–	–	–
Syrian Arab Republic	–	–	–	–	–
Tunisia	–	–	–	–	–
Turkey	–	–	[30]	N	Y
United Arab Emirates	[31], [32]	–	–	N	N
Western Sahara	–	–	–	–	–
Yemen	[33]	–	–	N	N
North America, High Income					
Canada	–	[34], [35], [36]	–	Y	Y
United States of America	[37], [38], [39], [40]	[2], [41]	[2], [39]	Y	Y
Oceania					
American Samoa	–	–	–	–	–
Cook Islands	–	–	–	–	–
Fiji	–	–	–	–	–
French Polynesia	–	–	–	–	–
Guam	–	–	–	–	–
Kiribati	–	–	–	–	–
Marshall Islands	–	–	–	–	–
Micronesia (Federated States of)	–	–	–	–	–
Nauru	–	–	–	–	–
New Caledonia	–	–	–	–	–
Niue	–	–	–	–	–
Northern Mariana Islands	–	–	–	–	–
Palau	–	–	–	–	–
Papua New Guinea	–	–	–	–	–
Pitcairn	–	–	–	–	–
Samoa	–	–	–	–	–
Solomon Islands	–	–	–	–	–
Tokelau	–	–	–	–	–
Tonga	–	–	–	–	–
Tuvalu	–	–	–	–	–
Vanuatu	–	–	–	–	–
Wallis and Futuna Islands	–	–	–	–	–
Sub-Saharan Africa, Central					
Angola	–	–	–	–	–
Central African Republic	–	–	–	–	–

Region /Country	CD – Past month prevalence (PMP)	CD – Past year prevalence (PYP)	CD – Lifetime prevalence (LP)	Age-specific Estimates	Sex-specific Estimates
Congo	–	–	–	–	–
Congo (Democratic Republic of)	–	–	–	–	–
Equatorial Guinea	–	–	–	–	–
Gabon	–	–	–	–	–
Sub-Saharan Africa, East					
Burundi	–	–	–	–	–
Comoros	–	–	–	–	–
Djibouti	–	–	–	–	–
Eritrea	–	–	–	–	–
Ethiopia	–	–	–	–	–
Kenya	–	–	–	–	–
Madagascar	–	–	–	–	–
Malawi	–	–	–	–	–
Mozambique	–	–	–	–	–
Rwanda	–	–	–	–	–
Somalia	–	–	–	–	–
Sudan	–	–	–	–	–
Tanzania (United Republic of)	–	–	–	–	–
Uganda	–	–	–	–	–
Zambia	–	–	–	–	–
Sub-Saharan Africa, Southern					
Botswana	–	–	–	–	–
Lesotho	–	–	–	–	–
Namibia	–	–	–	–	–
South Africa	–	–	–	–	–
Swaziland	–	–	–	–	–
Zimbabwe	–	–	–	–	–
Sub-Saharan Africa, West					
Benin	–	–	–	–	–
Burkina Faso	–	–	–	–	–
Cameroon	–	–	–	–	–
Cape Verde	–	–	–	–	–
Chad	–	–	–	–	–
Cote d'Ivoire	–	–	–	–	–
Gambia	–	–	–	–	–
Ghana	–	–	–	–	–
Guinea	–	–	–	–	–

Region /Country	CD – Past month prevalence (PMP)	CD – Past year prevalence (PYP)	CD – Lifetime prevalence (LP)	Age-specific Estimates	Sex-specific Estimates
Guinea-Bissau	–	–	–	–	–
Liberia	–	–	–	–	–
Mali	–	–	–	–	–
Mauritania	–	–	–	–	–
Niger	–	–	–	–	–
Nigeria	[42]	[2]	[2]	Y	Y
Saint Helena	–	–	–	–	–
Sao Tome and Principe	–	–	–	–	–
Senegal	–	–	–	–	–
Sierra Leone	–	–	–	–	–
Togo	–	–	–	–	–

3.2 Remission data

Data pertaining to remission of conduct disorder were derived from general population cohort studies, and naturalistic longitudinal studies of outpatient samples or samples identified through case registers. Remission was defined as no longer meeting diagnostic criteria for conduct disorder. Studies that reported a follow-up of less than two years were excluded, as were those reporting on the same cohort.

Work is continuing on sourcing and extracting data for remission of conduct disorder. Preliminary estimates and calculations will be available in January 2009.

3.3 Mortality data

Estimates of excess mortality are sought for each disorder. Where a high quality meta-analysis of excess mortality has been carried out, the derived mortality measurement will be used, with clear documentation of the source of data and authors of the study.

The data is currently being collated and estimates will be available in January 2009.

4.0 Principles for data manipulation and imputation

4.1 Prevalence estimates – data manipulation and imputation

Missing past month prevalence estimates

Many studies report the 'lifetime' risk of mental disorders but not past month prevalence. A decision was made to apply the observed proportions, derived from studies that reported prevalence of lifetime, 12-month and past month mental disorders, to countries that only reported lifetime or 12-month cases. Where possible, and based upon studies rated as being of sufficiently high quality, region-specific proportions of past year cases among lifetime cases were applied (population-weighted if estimates were available from more than one country).

Missing age-specific estimates

Many studies only report an estimate for one overall age range, whereas the GBD study requires more age-specific estimates. A decision was made to apply the observed age pattern from countries that reported age-specific prevalence to countries where that data is not available. Where possible, and based upon studies rated as being of sufficiently high quality, region-specific rate ratios will be applied.

Missing sex-specific estimates

Some studies do not report a male/female specific estimate. A decision was made to apply the observed sex ratios from countries that reported male and female estimates to countries that reported only an overall prevalence estimate. Where possible and based on studies rated as being of sufficiently high quality, region-specific sex ratios will be applied (population-weighted if estimates were available from more than one country).

No direct country-specific estimates of prevalence of any sort

Further attempts will be made to source prevalence data for countries for which no data has yet been found through searching all available sources (grey literature, contacting experts, national and NGO websites). Where no direct estimates of any sort are available, the weighted region-specific estimate, derived from studies in other countries within the region, will be applied (population-weighted if estimates were available from more than one country).

No direct region-specific estimates of prevalence of any sort

Further attempts will be made to source any prevalence data for that region through all available routes (grey literature, contacting experts, national and NGO websites). Where no direct estimates of any sort are available, the region will be matched to other regions (based on population characteristics identified through sensitivity analysis), and the weighted region-specific estimate will be applied (population-weighted if estimates were available from more than one country).

Data for 1990 or 2005 are not available.

If no direct estimates are available for 1990 or 2005, but data is available for other years, attempts will be made to estimate any trend across time. If only one estimate is available and no direct estimates of trend can be made, data on trends from other countries within the same region will be used.

Multiple data sources are available for the same country and time period.

Where multiple studies have been reported for the same country in the same time period, those of low quality or not considered representative will be excluded after careful consideration, and the estimates from the remaining countries will be pooled and the median value calculated. Statistical advice will be sought on the calculation of confidence intervals around the derived median value.

Implausible estimates

Where estimates reported are thought to be implausible, based on expert opinion, possibly due to cultural differences within the survey instrument, case ascertainment or sample selection, researchers will use indirect sources to compile estimates of what the prevalence might look like if imputations are required. This can then be used as a baseline comparison for the reported estimates.

4.2 First steps of data manipulation and imputation

The first steps of data manipulation, using decision rules agreed upon by the Expert group, have begun. Each study reporting prevalence for conduct disorder was reviewed to determine whether multiple prevalence types (LP, PYP, PMP) were reported. Only one study [39] was identified, which reported past month and lifetime prevalence estimates for two consecutive

years of the study. These estimates, were used to calculate a ratio of lifetime prevalence relative to past month prevalence.

The mean for these ratios of LP to PMP, are 7.13 : 1 for females and 8.98 : 1 for males.

A further search of the literature will be undertaken, as well as consultations with experts in the field, to obtain more information on likely ratios of lifetime and past year prevalence to past month prevalence.

4.3 Remission estimates – data manipulation and imputation

Remission rates

Where several remission data sources are available across different follow-up periods, the annualised remission rates (ARR) will be calculated and pooled as per methodology described by Mathers and colleagues [43] and Saha and colleagues[44].

ARR weighted (%)

$d = \sum[a*\{(-\ln(1 - b))/c\}]/\sum a$

The pooled annualised remission rate will be used across all countries. While it is acknowledged that remission may differ in countries where treated prevalence differs, insufficient data (country-specific treated prevalence and difference in remission rate by country) are available to estimate country- or region-specific remission rates.

4.4 Mortality estimates – data manipulation and imputation

Mortality rates

The derived estimate for excess mortality will be used across all countries. While it is acknowledged that mortality may differ in countries where treated prevalence differs, insufficient data (country-specific treated prevalence and country-specific excess mortality estimates) are available to estimate country- or region-specific remission rates.

References

1. Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., et al., *Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.* JAMA, 2000. **283**(15): p. 2008-12.
2. *World Mental Health Survey*. 2008, WHO.
3. Leung, P.W., Hung, S.F., Ho, T.P., Lee, C.C., Liu, W.S., Tang, C.P., et al., *Prevalence of DSM-IV disorders in Chinese adolescents and the effects of an impairment criterion : A pilot community study in Hong Kong.* European Child & Adolescent Psychiatry, 2008.
4. Gau, S.S.F., Chong, M.Y., Chen, T.H.H., and Cheng, A.T.A., *A 3-year panel study of mental disorders among adolescents in Taiwan.* American Journal of Psychiatry, 2005. **162**(7): p. 1344-50.
5. Mullick, M.S.I. and Goodman, R., *The prevalence of psychiatric disorders among 5-10 year olds in rural, urban and slum areas in Bangladesh: An exploratory study.* Social Psychiatry and Psychiatric Epidemiology, 2005. **40**(8): p. 663-671.
6. Pillai, A., Patel, V., Cardozo, P., Goodman, R., Weiss, H.A., and Andrew, G., *Non-traditional lifestyles and prevalence of mental disorders in adolescents in Goa, India.* British Journal of Psychiatry, 2008. **192**(1): p. 45-51.
7. Srinath, S., Girimaji, S.C., Gururaj, G., Seshadri, S., Subbakrishna, D.K., Bhola, P., et al., *Epidemiological study of child & adolescent psychiatric disorders in urban & rural areas of Bangalore, India.* Indian Journal of Medical Research, 2005. **122**(1): p. 67-79.
8. Kasmini, K. and al., E., *A prevalence survey of mental disorders among children in a rural Malaysian village.* Acta Psychiatrica Scandinavica, 1993. **87**: p. 253-7.
9. Sawyer, M., Miller-Lewis, L., and Clark, J., *The mental health of 13-17 year-olds in Australia: Findings from the National Survey of Mental Health and Well-Being.* Journal of Youth and Adolescence, 2007. **36**(2): p. 185--194.
10. Fergusson, D.M., Horwood, L., and Lynskey, M.T., *Prevalence and comorbidity of DSM-III--R diagnoses in a birth cohort of 15 year olds.* Journal of the American Academy of Child & Adolescent Psychiatry, 1993. **32**(6): p. 1127-1134.
11. Fergusson, D.M. and Horwood, J.L., *The Christchurch Health and Development Study: review of findings on child and adolescent mental health.* Australian and New Zealand Journal of Psychiatry, 2001. **35**(3): p. 287 - 296.
12. Anderson, J.C., Williams, S., McGee, R., and Silva, P.A., *DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population.* Archives of General Psychiatry, 1987. **44**(1): p. 69-76.
13. McGee, R., Feehan, M., Williams, S., Partridge, F., Silva, P.A., and Kelly, J., *DSM-III disorders in a large sample of adolescents.* Journal of the American Academy of Child & Adolescent Psychiatry, 1990. **29**(4): p. 611-9.
14. Feehan, M., McGee, R., Raja, S.N., and Williams, S.M., *DSM-III-R disorders in New Zealand 18-year-olds.* Australian & New Zealand Journal of Psychiatry, 1994. **28**(1): p. 87-99.
15. Bird, H.R., Davies, M., Duarte, C.S., Shen, S.A., Loeber, R., and Canino, G.J., *A study of disruptive behavior disorders in Puerto Rican youth: II. Baseline prevalence, comorbidity, and correlates in two sites. .* Journal of the American Academy of Child and Adolescent Psychiatry, 2006. **45**(9): p. 1042-1053.
16. Canino, G.P., Shrout, P.E.P., Rubio-Stipec, M.S., Bird, H.R.M.D., Bravo, M.P., Ramirez, R.P., et al., *The DSM-IV Rates of Child and Adolescent Disorders in Puerto Rico: Prevalence, Correlates, Service Use, and the Effects of Impairment.* Archives of General Psychiatry, 2004. **61**(1): p. 85-93.
17. Puura, K., Almqvist, F., Tamminen, T., Piha, J., Rasanen, E., Kumpulainen, K., et al., *Psychiatric disturbances among prepubertal children in southern Finland.* Social Psychiatry & Psychiatric Epidemiology, 1998. **33**(7): p. 310-8.
18. Fombonne, E., *The Chartres Study 1: Prevalence of psychiatric disorders among French school-aged children.* British Journal of Psychiatry, 1994. **164**: p. 69-79.

19. Esser, G., Schmidt, M.H., and Woerner, W., *Epidemiology and course of psychiatric disorders in school-age children--results of a longitudinal study.* Journal of Child Psychology & Psychiatry & Allied Disciplines, 1990. **31**(2): p. 243-63.
20. Verhulst, F.C., Van der Ende, J., Ferdinand, R.F., and Kasius, M.C., *The prevalence of DSM-III-R diagnoses in a national sample of dutch adolescents.* Archives of General Psychiatry, 1997. **54**(4): p. 329-336.
21. Heiervang, E., Stormark, K.M., Lundervold, A.J., Heimann, M., Goodman, R., Posserud, M.-B., et al., *Psychiatric Disorders in Norwegian 8- to 10-Year-Olds: An Epidemiological Survey of Prevalence, Risk Factors, and Service Use. [Article].* Journal of the American Academy of Child & Adolescent Psychiatry, 2007. **46**(4): p. 438-447.
22. Meltzer, H., Gatward, R., Goodman, R., and Ford, T., *The mental health of children and adolescents in Great Britain*. 2000, Office for National Statistics.
23. Green, H., McGinnty, A., Meltzer, H., Ford, T., and Goodman, R., *Mental Health of Children and Young People in Great Britain, 2004.* UK National Statistics, 2004: p. 1-156.
24. Ford, T., Goodman, R., and Meltzer, H., *The British child and adolescent mental health survey 1999: The prevalence of DSM-IV disorders.* Journal of the American Academy of Child and Adolescent Psychiatry, 2003. **42**(10): p. 1203-1211.
25. Maughan, B., Rowe, R., Messer, J., Goodman, R., and Meltzer, H., *Conduct disorder and oppositional defiant disorder in a national sample: developmental epidemiology.* Journal of Child Psychology & Psychiatry & Allied Disciplines, 2004. **45**(3): p. 609-21.
26. Pineda, D.A. and Puerta, I.C., *[Prevalence of dissocial conduct disorder in adolescents using an epidemiological diagnostic questionnaire].* Revista de Neurologia, 2001. **32**(7): p. 612-8.
27. Medina-Mora, M.E., Borges, G., Benjet, C., Lara, C., and Berglund, P., *Psychiatric disorders in Mexico: lifetime prevalence in a nationally representative sample.* The British Journal of Psychiatry, 2007. **190**(6): p. 521-528.
28. Fleitlich-Bilyk, B. and Goodman, R., *Prevalence of Child and Adolescent Psychiatric Disorders in Southeast Brazil.* Journal of the American Academy of Child & Adolescent Psychiatry June, 2004. **43**(6): p. 727-734.
29. Al-Jawadi, A.A. and Abdul-Rhman, S., *Prevalence of childhood and early adolescence mental disorders among children attending primary health care centers in Mosul, Iraq: a cross-sectional study.* BMC Public Health, 2007. **7**: p. 274.
30. Dogan, O., Onder, Z., Dogan, S., and Akyuz, G., *Distribution of symptoms of conduct disorder and antisocial personality disorder in Turkey.* Psychopathology, 2004. **37**(6): p. 285-9.
31. Eapen, V., Al-Gazali, L., Bin-Othman, S., and Abou-Saleh, M., *Mental Health Problems Among Schoolchildren in United Arab Emirates: Prevalence and Risk Factors.* Journal of the American Academy of Child & Adolescent Psychiatry, 1998. **37**(8): p. 880-886.
32. Eapen, V., Al-Sabosy, M., Saeed, M., and Sabri, S., *Child psychiatric disorders in a primary care Arab population.* International Journal of Psychiatry in Medicine, 2004. **34**(1): p. 51-60.
33. Alyahri, A. and Goodman, R., *The prevalence of DSM-IV psychiatric disorders among 7-10 year old Yemeni schoolchildren.* Social Psychiatry and Psychiatric Epidemiology, 2008. **43**(3): p. 224-230.
34. Breton, J.-J., Bergeron, L., Valla, J.-P., Berthiaume, C., Gaudet, N., Lambert, J., et al., *Quebec Child Mental Health Survey: Prevalence of DSM-III--R mental health disorders.* Journal of Child Psychology and Psychiatry, 1999. **40**(3): p. 375-384.
35. Romano, E., Tremblay, R., Vitaro, F., Zoccolillo, M., and Pagini, L., *Prevalence of Psychiatric Diagnoses and the Role of Perceived Impairment: Findings from an Adolescent Community Sample.* Journal of Child Psychology and Psychiatry and Allied Disciplines, 2001. **42**(4): p. 451.
36. Offord, D.R., Boyle, M.H., and Racine, Y., *Ontario Child Health Study: Correlates of Disorder.* Journal of the American Academy of Child & Adolescent Psychiatry, 1989. **28**(6): p. 856-60.
37. Kashani, J.H., Beck, N.C., Hoeper, E.W., Fallahi, C., Corcoran, C.M., McAllister, J.A., et al., *Psychiatric disorders in a community sample of adolescents [published erratum appears in Am J Psychiatry 1987 Aug;144(8):1114].* American Journal of Psychiatry, 1987. **144**(5): p. 584-589.

38. Velez, C.N., Johnson, J., and Cohen, P., *A longitudinal analysis of selected risk factors of childhood psychopathology.* Journal of the American Academy of Child & Adolescent Psychiatry, 1989. **28**(6): p. 861-4.
39. Lewinsohn, P.M., Hops, H., Roberts, R.E., Seeley, J.R., and Andrews, J.A., *Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students.* Journal Of Abnormal Psychology, 1993. **102**(1): p. 133-144.
40. Cohen, P., Cohen, J., Kasen, S., Velez, C.N., Hartmark, C., Johnson, J., et al., *An epidemiological study of disorders in late childhood and adolescence--I. Age- and gender-specific prevalence.* Journal of Child Psychology & Psychiatry & Allied Disciplines, 1993. **34**(6): p. 851-67.
41. Costello, E.J., Mustillo, S., Erkanli, A., Keeler, G., and Angold, A., *Prevalence and development of psychiatric disorders in childhood and adolescence.* Archives of General Psychiatry, 2003. **60**(8): p. 837-844.
42. Abiodun, O.A., *Emotional illness in a paediatric population in Nigeria.* East African Medical Journal, 1992. **69**(10): p. 557-9.
43. Mathers, C.D., Vos, T., Lopez, A.D., Solomon, J., and Ezzati, M., eds. *National burden of disease studies: a practical guide. Global program on evidence for health policy.* 2001, World Health Organisation: Geneva.
44. Saha, S., Barendregt, J.J., Vos, T., Whiteford, H., and McGrath, J., *Modelling disease frequency measures in schizophrenia epidemiology.* Schizophrenia Research, 2008. **104**(1-3): p. 246-254.

Appendix

Flowchart of systematic data search for Mental Disorders